Study of CAP-1002 to benefit skeletal muscle function in boys and young men with advanced Duchenne muscular dystrophy (DMD)

Trial Profile

Study of CAP-1002 to benefit skeletal muscle function in boys and young men with advanced Duchenne muscular dystrophy (DMD)

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs CAP-1002 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms HOPE-2
  • Sponsors Capricor Therapeutics
  • Most Recent Events

    • 29 Nov 2017 According to a Capricor Therapeutics media release, data from this trial will subject to a Biologics License Application (BLA) to obtain marketing approval of CAP-1002.
    • 29 Nov 2017 According to a Capricor Therapeutics media release, the US FDA has cleared IND application to initiate this trial. The national principal investigator for the HOPE-2 trial will be Craig M. McDonald.
    • 04 Oct 2017 According to a Capricor Therapeutics media release, this trial may potentially serve as a registrational study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top